Crispr cans a next-gen project
The CD70-targeting CTX131 heads for the scrapheap.
Lyell shuffles the pipeline again
After more discontinuations, a new deal brings in fresh blood.
SITC 2025 – fresh hope for Summit's Harmoni
Harmoni-A hits, backing a quiet disclosure about the Harmoni trial.
An ozekibart reminder about liver toxicity
Inhibrx reveals three deaths in phase 1, but all predate screening protocols.
BeOne joins the Kat6 pack
BG-75202 features among several projects starting first-in-human trials.
Pfizer moves into the VEGF bispecific fast lane
There will soon be three PD-(L)1 x VEGF projects in pivotal lung and colorectal cancer trials.
Nuvation reroutes its glioma plan
The company will no longer initiate a head-to-head trial of safusidenib against Voranigo.
Venture capitalists buy into TROP2
Blackstone follows Abingworth, but why?
